Artivion, Inc. AORT 深 滬
已收盤 05-08 16:00:00 美东时间
25.41
-10.010
-28.26%
華盛通- 最 高27.31
- 今 開27.31
- 成交量 513.70万股
- 最 低 19.16
- 昨 收 35.42
- 總市值 12.32亿
- 52周最高 48.25
- 市盈率 靜 122.81
- 換手率 10.59%
- 52周最低 19.16
- 委 比 -3.74%
- 總股本 4849.60万
- 歷史最高 48.25
- 量 比 11.57
- 振 幅 23.01%
- 歷史最低 3.82
- 每 手 1
- 風險率 5.84%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股周涨跌榜 | 多只绩优股狂飙！Rackspace周内狂涨210%，DigitalOcean周涨近60%股价再创新高
多只绩优股狂飙！Rackspace周内狂涨210%，DigitalOcean周涨近60%股价再创新高；AI“带飞”建筑巨头业绩！斯特林建筑周涨逾58%>>
05-09 10:06
Needham Maintains Buy on Artivion, Lowers Price Target to $44
Needham analyst Mike Matson maintains Artivion (NYSE:AORT) with a Buy and lowers the price target from $58 to $44.
05-08 18:48
U.S. RESEARCH ROUNDUP-Applied Materials, McDonald's, McKesson
U.S. RESEARCH ROUNDUP-Applied Materials, McDonald's, McKesson May 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Applied Materials, McDonald's and McKesson on Friday. HIGHLIGHTS * Applied Materials Inc AMAT.O : Berenb
05-08 15:12
Artivion Earnings Call Highlights Growth Amid Headwinds
Artivion Inc. (($AORT)) has held its Q1 earnings call. Read on for the main hig...
05-08 08:25
Artivion Acquires Endospan to Expand Aortic Arch Portfolio
Artivion ( ($AORT) ) has shared an announcement. On May 7, 2026, Artivion repor...
05-08 05:16
Artivion shares are trading lower after the company reported Q1 financial results and cut its FY26 sales guidance with its midpoint below estimates.
Artivion shares are trading lower after the company reported Q1 financial resul...
05-08 05:15
Artivion Lowers FY2026 Sales Guidance from $486.000M-$504.000M to $480.000M-$496.000M vs $495.284M Est
Artivion (NYSE:AORT) lowers FY2026 sales outlook from $486.000 million-$504.000 million to $480.000 million-$496.000 million vs $495.284 million estimate.
05-08 04:27
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
Needham Reiterates Buy on Artivion, Maintains $58 Price Target
Needham analyst Mike Matson reiterates Artivion (NYSE:AORT) with a Buy and maintains $58 price target.
04-08 01:41
The FDA Approves Premarket Approval Application For NEXUS Aortic Arch System, Developed By Artivion's Partner; The Approval Entitles Artivion To Exercise Its Option To Acquire Endospan At Any Time Within 90 Days
Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA)
04-07 19:08
